<DOC>
	<DOCNO>NCT01626833</DOCNO>
	<brief_summary>Anorexia nervosa may responsible catch- even interruption growth , delay puberty osteopenia failure acquisition bone mass . The recovery normal nutrition usually lead resumption growth pubertal development . However , despite therapeutic nutritional psychotherapeutic satisfactory approach , patient significant short stature reduce adult final height deficit bone mass . The main objective evaluate effect growth hormone ( hGH ) treatment growth velocity prepubertal child child early puberty anorexia nervosa significant reduction height velocity . This single-center , control , randomize double-blind clinical trial evaluate efficacy hGH treatment 1 year placebo , growth velocity prepubertal child early puberty Anorexia nervosa major catch-down.This period follow evaluation hGH treatment child receive placebo continue hGH treatment treatment arm 1 year , total 2 year study child . This second period correspond ethical consideration give secondarily access treatment patient placebo group .</brief_summary>
	<brief_title>Severe Decrease Growth Velocity Children With Anorexia Nervosa.Therapeutic Trial Growth Hormone</brief_title>
	<detailed_description>Patients evaluate baseline 3 , 6 , 9 , 12 , 15 , 18 , 21 24 month start trial . This evaluation include clinical evaluation biological ( IGF-I , IGFBP-3 , leptin , ghrelin , adiponectin , mineral metabolism , thyroid function , 24 hour urinary cortisol , well conventional electrolyte tolerance parameter ) , psychological nutritional study body composition absorptiometry 0 , 12 24 month . Evaluations conduct Center Clinical Investigation Hospital Robert Debre . The primary endpoint linear growth rate 1 year start trial express cm/1 year group hGH compare placebo group . The secondary endpoint height velocity express SDS ( standard deviation score ) , data body composition psychological change assess 2 arm end two year clinical trial . The data body composition obtain dual photon absorptiometry biological data mineral metabolism growth factor express Z score compare normal reference establish France , healthy subject accord age , gender pubertal stage .</detailed_description>
	<mesh_term>Anorexia Nervosa</mesh_term>
	<mesh_term>Anorexia</mesh_term>
	<mesh_term>Bone Diseases , Metabolic</mesh_term>
	<mesh_term>Puberty , Delayed</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Medical screening . Female male subject age 816 year 11 month , clinical anorexia nervosa / reference diagnostic criterion DSMIV ( 1 ) early puberty ( Tanner stage 1 2 ) prolong CatchDown least 18 month ( HV ≤ 2 cm / year ) , bone age ≤ 12 year girls ≤14 year boys . Anorexia nervosa diagnose least 1 year study Growth velocity document least 18 month inclusion As child severe CatchDown assessment GH secretion must perform inclusion ( context care ) trial , condition GH peak value : GH value &lt; 20 miu / L lead production brain MRI ( context care ) normal ( normal hypothalamicpituitary axis absence tumor pathology ) allow Inclusion patient . Normal glucose tolerance Stable metabolic state weight gain least 10 % body weight time body mass index low relation occurrence disease normal blood electrolyte ( hypokalemia ) . Subjects whose holder sign parental consent Subjects whose holder parental authority affiliate social security scheme CMU ( CMU universal medical coverage ) . Subjects midpuberty ( Tanner stage 3 4 ) menarche . Subjects chromosomal abnormality chronic disease associate chronic require longterm treatment . Impaired glucose tolerance diabetes . Inability patient medical team ensure progress monitoring protocol . Participation another trial . Bradycardia ≤ 50 bpm . Children whose holder parental authority beneficiary social security Contraindication SOMATROPINE</criteria>
	<gender>All</gender>
	<minimum_age>8 Years</minimum_age>
	<maximum_age>203 Months</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>anorexia nervosa</keyword>
	<keyword>GH</keyword>
	<keyword>Growth velocity</keyword>
</DOC>